Loading
companiesCompany
Imagene AI
Imagene AI trains large artificial intelligence models on ordinary stained biopsy images so that, within minutes, a slide can predict which gene changes a lung tumour carries, helping doctors decide on targeted drugs before slower genetic tests return.
Overview
Imagene AI develops foundation-model based digital pathology for precision oncology. Its CanvOI model, trained on more than 1.5 million biopsy images, underpins an Oncology Intelligence Engine combining imaging, molecular and clinical data for biomarker discovery, patient stratification and companion diagnostic development. The Lung Prediction Panel, offered for research use from a CAP-accredited laboratory (March 2025), predicts eight actionable alterations in non-small cell lung cancer from H&E slides in minutes: EGFR, KRAS G12C, ERBB2 and BRAF V600E mutations, ALK, RET and ROS1 fusions and MET exon 14 skipping. Partnerships include Tempus (2025), Daiichi Sankyo (2026), Proscia's alliance for AI-powered IHC companion diagnostics (2026) and Tel Aviv Sourasky Medical Center. In July 2025 the company closed a $23 million Series B led by Larry Ellison, for $45 million raised in total.
Headquarters
Miami, FL, US
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Led by Larry Ellison with Aguras Pathology Investments, July 2025; total funding $45 million. Source is the company release distributed via Newswire.com. | 2025 | $23M | newswire.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- The Series B release dateline is Miami; the company has Israeli origins and works closely with Tel Aviv hospitals, so Tel Aviv may still be the R&D base. The www.imagene-ai.com host does not resolve; the canonical site is imagene-ai.com. Founding year not sourced.
Similar pages
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
- CompanyLucence
- Key paperClinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer
- Key paperProspective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
- PersonKoichi Goto
Shares RET, MET, HER2, Non-small-cell lung cancer.
- Key paperLemmon and Schlessinger 2010: cell signalling by receptor tyrosine kinases
- CompanyIbex Medical Analytics
Shares Companion diagnostics, Digital pathology & AI, HER2.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares ALK, EGFR, KRAS, Non-small-cell lung cancer.